TORONTO, Oct. 1 /CNW/ - Bradmer Pharmaceuticals Inc., a biopharmaceutical
company dedicated to the development and commercialization of cancer
therapies, announced today that Dr. Alan M. Ezrin, President and Chief
Executive Officer of the Company, will present a corporate update at
BioContact Québec 2008, which is being held in Québec City from October 1st -
3rd at the Château Frontenac. Dr. Ezrin will provide an update on the
Company's ongoing Phase III trial of Neuradiab(TM), a treatment for newly
diagnosed glioblastoma multiforme (GBM), and outline its business development
plans for 2009. The presentation will take place on Thursday, October 2nd at
4:00pm ET in the Laval Room and Dr. Ezrin will be available for questions
following his presentation.
